Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$3.61
Change (%) Stock is Down 0.04 (1.10%)
Volume83,284
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
10/03/18TRU NIAGEN® PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting
Women’s health practitioners now have access to TRU NIAGEN® PRO for aging patients LOS ANGELES, Oct. 03, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it will highlight its new TRU NIAGEN® PRO product at the NAMS Annual Meeting 2018 in San Diego, CA, beginning today through Oct. 6. “Aging is so much more than skin deep—down to the cellular level. NAD (nicotinamide adenine dinucleotide) is critical for mitochondria function, and healthy mitochondria are a vital... 
Printer Friendly Version
10/02/18ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific
LOS ANGELES, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Yan Chu as Managing Director, Asia Pacific, effective today. Based in Singapore, Chu will lead the TRU NIAGEN® business for the region. Chu is joining ChromaDex from Comvita, an international health products company, where she served as Regional General Manager overseeing the Hong Kong, Japan, and Korea markets. Previously, Chu led sales and marketing functions in the Asia Paci... 
Printer Friendly Version
09/24/18TRU NIAGEN® Earns NSF International’s Certified for Sport® Certification
Addressing professional athletes, trainers and active consumers, TRU NIAGEN product rigorously tested and does not contain over 272 athletic banned substances IRVINE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced its TRU NIAGEN product recently earned certification from NSF International’s... 
Printer Friendly Version
What's New
DateTitle
09/05/18
September 2018 Investor Presentation PDF
08/09/18
Q2 2018 Earnings Presentation PDF
07/17/18
July 2018 Investor Presentation PDF
08/09/18
2018 Q2 Quarterly Report on Form 10Q PDF
04/27/18
2018 Proxy Statement  PDF
03/15/18
2017 Annual Report on Form 10-K PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.